ArticleScientific reports2026
Identification and experimental validation of biomarkers associated with exercise in intervertebral disc degeneration through bulk RNA and single-cell RNA sequencing analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term running positively affects the intervertebral disc. This study aimed to identify and validate biomarkers associated with exercise-related genes (ERGs) in intervertebral disc degeneration (IDD), potentially guiding the development of targeted therapies. IDD-related datasets and ERGs were extracted from public databases. Biomarkers were identified through differential expression analysis, weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) networks, machine learning techniques, and gene expression analyses. A nomogram based on these biomarkers was developed and evaluated. Subsequently, functional enrichment, RNA methylation, drug prediction, molecular docking, and single-cell RNA sequencing (scRNA-seq) analyses were performed. Finally, reverse transcription quantitative PCR (RT-qPCR) was conducted to validate the expression of biomarkers. TNFAIP6 and CHI3L1 were identified as biomarkers for IDD, both exhibiting significantly higher expression in IDD samples. These findings were corroborated by RT-qPCR. A nomogram was developed and validated, with the calibration curve indicating its effectiveness in predicting IDD risk (P = 0.798 in the Hosmer-Lemeshow test). All biomarkers were significantly co-enriched in the "spliceosome" pathway. Additionally, compound 16 was found to target CHI3L1, while acetylsalicylic acid was predicted to target TNFAIP6. Molecular docking analysis revealed favorable binding energies between the compounds and biomarkers, including a binding energy of -9.1 kcal/mol between compound 16 and CHI3L1. Finally, scRNA-seq analysis identified homeostatic fibroblasts, progenitor cells, fibrochondrocytes, and regulatory chondrocytes as key cell types in IDD, with dynamic expression patterns of CHI3L1 observed during the differentiation of these key cells. Biomarkers associated with exercise, specifically TNFAIP6 and CHI3L1, were identified. These findings provide valuable insights for the development of targeted therapies for patients with IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.